Long-term follow-up of patients with type 1 diabetes transplanted with neonatal pig islets.
Pancreas transplantation is an option to achieve better metabolic control and decrease chronic complications in patients with diabetes. Xenotransplantation becomes an important alternative. In this study, we show the clinical outcome of patients with type 1 diabetes transplanted with neonatal pig islets without immunosuppression. In a longitudinal study of 23 patients with type 1 diabetes, who received porcine islets between 2000 and 2004, we registered demographic and clinical characteristics every 3 months and chronic complications evaluation yearly. Porcine C-peptide was measured in urine samples under basal conditions and after stimulation with l-arginine. More than 50% were female, median current age was 20·8 years, median diabetes duration at transplantation 5·5 years, median current diabetes duration 11 years and median time post-transplantation 5·7 years. Their media of glycosylated haemoglobin reduced significantly after the first transplantation. Insulin doses remain with a reduction greater than 33% in more than 50% of the patients. Before transplantation, 14 of the 21 patients presented mild chronic complications and currently only two patients presented these complications. Porcine C-peptide was present in all urine samples under basal conditions and increased post-stimulation with l-arginine. These patients achieved an excellent metabolic control after the first transplantation. This could explain, as well as the remaining function of transplanted cells, the low frequency of chronic complications compared to patients with similar diabetes duration and age.
Valdes-Gonzalez
R
R
Laboratorio de Terapia Celular, Hospital Infantil de México Federico Gómez, Mexico City, Mexico. rvaldes@axacell.com
Rodriguez-Ventura
A L
AL
White
D J G
DJ
Bracho-Blanchet
E
E
Castillo
A
A
Ramírez-González
B
B
López-Santos
M G
MG
León-Mancilla
B H
BH
Dorantes
L M
LM
D000293:Adolescent; D000818:Animals; D000831:Animals, Newborn; D002096:C-Peptide / Q000652:urine; D048909:Diabetes Complications / Q000517:prevention & control*; D003922:Diabetes Mellitus, Type 1 / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D016381:Islets of Langerhans Transplantation; D008297:Male; D013552:Swine; D013997:Time Factors; D014183:Transplantation, Heterologous; D055815:Young Adult
D002096:C-Peptide; D006442:Glycated Hemoglobin; C517652:hemoglobin A1c protein, human